Who
Edward J. Dulac III
EVP, Chief Financial Officer
Company insider
Files Form 4 as: EVP, Chief Financial Officer, Intellia Therapeutics; Chief Financial Officer, Fate Therapeutics.
In numbers
- Trades disclosed
- 45
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $3.5M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 17 Aug 2020
- Last trade
- 22 Jul 2026
- Last filed
- 24 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jul 2026filed 24 Jul 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $91K8,111 at $11.25 | filing |
| 22 Jul 2026filed 24 Jul 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $91K8,111 at $11.25 | filing |
| 2 Jul 2026filed 6 Jul 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $84K4,677 at $18.00 | filing |
| 2 Jul 2026filed 6 Jul 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $84K4,677 at $18.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —61,280 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —87,543 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —87,543 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —61,280 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $59K6,379 at $9.21 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $59K6,379 at $9.21 | filing |
| 23 Jul 2025filed 25 Jul 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $105K7,462 at $14.02 | filing |
| 1 Mar 2025filed 4 Mar 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —67,429 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —47,200 at $0.00 | filing |
| 22 Jul 2024filed 24 Jul 2024 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —96,219 at $0.00 | filing |
| 22 Jul 2024filed 24 Jul 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —66,324 at $0.00 | filing |
| 4 Mar 2024filed 5 Mar 2024 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K2,447 at $7.77 | filing |
| 1 Feb 2024filed 2 Feb 2024 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —425,000 at $0.00 | filing |
| 29 Jan 2024filed 30 Jan 2024 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,2451,849 at $5.00 | filing |
| 9 Jan 2024filed 10 Jan 2024 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $31K7,028 at $4.37 | filing |
| 2 Jan 2024filed 3 Jan 2024 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K5,182 at $3.66 | filing |
News
Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)NTLA · themarketsdaily.com · 24 Oct 2026Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Edward J. Dulac III; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.